<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129427">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879176</url>
  </required_header>
  <id_info>
    <org_study_id>1095/2013</org_study_id>
    <nct_id>NCT01879176</nct_id>
  </id_info>
  <brief_title>Cytokine Removal in Cardiopulmonary Bypass Patients</brief_title>
  <acronym>CytoSorb</acronym>
  <official_title>EFFECT OF CYTOKINE REMOVAL IN CARDIOPULMONARY BYPASS PATIENTS USING THE CYTOSORB ™ FILTER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoSorbents Europe GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiopulmonary bypass (CPB) surgery initiates a systemic inflammatory response induced by
      extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit,
      endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation,
      ischemia-reperfusion injury of myocardium) factors. Monocytes are important players in
      systemic inflammation and the main producers of pro- and antiinflammatory cytokines.
      Monocytes activated by the extracorporeal circuit lead to a dysregulation of inflammatory
      homeostasis, increased levels of proinflammatory plasma mediators such as TNF-a, IL-1β, IL-6
      and  IL-18 are joined by antiinflammatory cytokines such as IL-10. This strong inflammatory
      response induces post surgical monocyte immunosuppression which is indicated by an impaired
      production of ex vivo LPS induced TNF-a production. Also malfunction of the peripheral
      circulation with increased lactate levels, pronounced fluid accumulation, increased need of
      vasopressors and cerebral dysfunction are observed. All of these factors may delay weaning
      from the ventilator, recovery of organ functions and discharge from ICU. Thus measures to
      decrease the inflammatory process have the potential to improve the perioperative course.

      Use of cytokine adsorbing circuit during CBP has an effect on circulation cytokine levels
      for the first 36 hours after surgery and induces a decreased inflammatory response for up to
      3 days post surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients, who have an elective cardiac surgical intervention with an expected CBP duration
      &gt;120 minutes (e.g.: valve surgery, coronary artery bypass graft (CABG), combined procedures)
      will be enrolled to the study after given informed consent.

      Patients, who decline will be asked to collect their secondary outcome data to create a
      &quot;real - life&quot; group and increase the number of patients in the control group. In this &quot;real
      - life&quot; group no additional blood samples will be taken.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evolution of cytokines IL-1β, IL-6, IL-18, TNF-α, IL-10</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CRP changes</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ex vivo LPS induced TNF-α production</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug treatment</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vasopressor dose
Insulin dose</description>
  </other_outcome>
  <other_outcome>
    <measure>Volemic status</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Need of fluid components (crystalloid, colloid solutions)
Need of blood products (erythrocytes, fresh frozen plasma, platelets)
Body impedance
Body weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in procalcitonin, albumin, fibrinogen and total blood count</measure>
    <time_frame>1. At induction of anaesthesia 2. Start CBP 3. At the end of CPB 4. 2 hours  5. 24 hours  6. 48 hours  7. 120 - 168 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>• Length of ICU stay</measure>
    <time_frame>participants will be followed for the duration of ICU stay</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>30 days mortality</measure>
    <time_frame>at day 30</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Elective Cardiac Surgical Interventions</condition>
  <arm_group>
    <arm_group_label>CytoSorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No filter will be installed on the CPB machine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <arm_group_label>CytoSorb</arm_group_label>
    <other_name>Polymer Based Adsorption Systems</other_name>
    <other_name>ISO 13485:2003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective cardiac surgical intervention with an expected CBP duration &gt;120 minutes

        Exclusion Criteria:

          -  Emergency procedures

          -  Heart transplantation

          -  Elective left ventricular assist device  (LVAD) implantation

          -  Pulmonary thromendarterectomy

          -  Declined informed consent

          -  Serum creatinine &gt; 2mg/dl

          -  Body mass index &lt; 18

          -  Age &lt; 18 years

          -  Pregnant woman

          -  Receiving chemotherapy or diagnosed with any disease state (e.g., AIDS) that has
             produced leukopenia

          -  Receiving antileukocyte drugs

          -  Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)

          -  CRP &gt; 2mg/dl

          -  History of Stroke

          -  Bilirubin &gt;2mg/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hiesmayr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin H Bernardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Rinösl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedrich Hoffelner</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Spittler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Wiedemann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp Opfermann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin H Bernardi, MD</last_name>
    <phone>+431404004109</phone>
    <email>martin.bernardi@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Rinösl, MD</last_name>
    <phone>+431404004109</phone>
    <email>harald.rinoesl@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Divison of Cardiothoracic Anaesthesia and Intensive Care, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin H Bernardi, MD</last_name>
      <phone>00431404004109</phone>
      <email>martin.bernardi@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Harald Rinösl, MD</last_name>
      <phone>00431404004109</phone>
      <email>harald.rinoesl@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Hiesmayr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin H Bernardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Martin Bernardi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
